Compare UVE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UVE | EVO |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 957.6M | 934.1M |
| IPO Year | 1996 | N/A |
| Metric | UVE | EVO |
|---|---|---|
| Price | $39.87 | $2.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $40.00 | $7.00 |
| AVG Volume (30 Days) | ★ 203.9K | 91.4K |
| Earning Date | 04-23-2026 | 04-08-2026 |
| Dividend Yield | ★ 1.97% | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 1.88 | N/A |
| Revenue | ★ $1,603,915,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $2.88 | $10.05 |
| P/E Ratio | $21.04 | ★ N/A |
| Revenue Growth | ★ 5.48 | N/A |
| 52 Week Low | $21.96 | $2.31 |
| 52 Week High | $41.96 | $4.80 |
| Indicator | UVE | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.92 | 46.32 |
| Support Level | $32.51 | $2.63 |
| Resistance Level | $41.58 | $3.78 |
| Average True Range (ATR) | 1.22 | 0.09 |
| MACD | -0.19 | -0.04 |
| Stochastic Oscillator | 52.06 | 33.38 |
Universal Insurance Holdings Inc is an insurance holding company. Through its subsidiaries, the company mainly offers property and casualty insurance and value-added insurance services. It develops, markets, and underwrites insurance products for consumers predominantly in the personal residential homeowners lines of business and performs all other insurance-related services for its primary insurance entities, including risk management, claims management, and distribution. The group offers the following types of personal residential insurance: homeowners, renters/tenants, condo unit owners, and dwelling/fire, through an independent agent network and online distribution channels across multiple states in the United States of America.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.